LEUKEMIA IN 2019 AND BEYOND
State of the art, recent developments, and future directions in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Get a Sample of This Report
Request a sample of this report and start discovering the insights
Report Topics Include
- CML: First-Line TKI Landscape (including RFS/TFR)
Kendra Sweet, MD - CML: Relapsed/Refractory and New Targets (including mutation testing)
Richard Stone, MD - ALL: Genetic Subsets
Charles Mullighan, MBBS, MSc, MD - ALL: Role of Monoclonal Antibodies
Elias Jabbour, MD - ALL: Role of CAR T Cells
Bijal Shah, MD - ALL: Measurable/Minimal Residual Disease
Aaron Logan, MD, PhD - MDS: Low-Risk Disease
Guillermo Garcia-Manero, MD - MDS: High-Risk Disease
Keith Stewart, MB, ChB - AML: Patient Subsets (including ELN classification, prognostic groups, unfit elderly)
Farhad Ravandi-Kashani, MD - AML: Targeting FLT3
Richard Stone, MD - AML: New Therapeutic Targets
Amir Fathi, MD - AML: Targeting BCL-2
Naval Daver, MD
Medical Expert Panel
Elias Jabbour, MD
Naval Daver, MD
Amir Fathi, MD
Guillermo Garcia-Manero, MD
Rami Komrokji, MD
Aaron Logan, MD, PhD
Charles Mullighan, MBBS, MSc, MD
Farhad Ravandi-Kashani, MD
Bijal Shah, MD
Richard M. Stone, MD
Kendra Sweet, MD, MS
Srdan Verstovsek, MD, PhD
